Nuveen Asset Management tilts AI bet from megacaps to network plumbing

The clearest statement of conviction this quarter is the decision to introduce Arista Networks at 0.35% of the book, a new stake worth about $1.25B. In an AI build-out where data-center bandwidth is becoming the bottleneck, Arista is a direct play on the switch and routing layer that hyperscalers cannot avoid.

Nuveen also leaned into enterprise AI and digital transformation plumbing rather than front-end hype. Adds to ServiceNow and Accenture — together boosting exposure by roughly $307.7M — position the portfolio for long-cycle IT service and workflow spending as companies embed AI into core processes.

On the cyclical side, Tesla and Boeing stand out. Nuveen lifted Tesla by +19.8% (about $876.5M of incremental capital) and boosted Boeing by +8.1% (about $92.1M), signaling a willingness to own volatile, controversy-laden industrials where embedded technology and long order books can drive outsized operating leverage when sentiment normalizes.

In health care, the firm is quietly skewing toward growth. Eli Lilly and UnitedHealth both saw incremental increases, adding a combined ~$175.6M, suggesting a preference for dominant, innovation-led franchises over slower, patent-cycle names. Fiserv, a core fintech infrastructure name, was also topped up, reinforcing Nuveen’s view that payments and transaction rails remain a secular winner even as they harvest some gains from card networks.

Nuveen’s biggest funding sources were exactly where you’d expect after a massive AI and big-tech run: Nvidia, Meta, Apple, Microsoft and Amazon. Nvidia’s stake was cut by -6.6% (about $1.45B), Meta by -12.2% (about $1.15B), with Apple and Microsoft trimmed more gently — classic risk management in positions that have swelled in size but remain core.

Alphabet was reduced in both share classes, and Amazon, Netflix and Booking were all scaled back. Across these names, Nuveen is effectively saying the market now recognizes the AI and digital advertising story; capital is better redeployed into less fully discounted infrastructure and implementation plays rather than adding to the most obvious winners.

Financials provided another chunk of liquidity. Wells Fargo was cut hard at -16.9% (about $352.7M), and JPMorgan, Bank of America and Progressive were all modestly trimmed. This looks less like a macro call on credit and more like a rotation away from rate-sensitive, regulation-heavy balance sheets into fee- and software-driven franchises.

Elsewhere, the scalpel came out in low-volatility staples and legacy pharma. Modest reductions in Prologis, Linde, Johnson & Johnson, Merck, AbbVie, and a basket of consumer names (Procter & Gamble, Starbucks, TJX, Disney) show Nuveen willing to sacrifice some defensive ballast to maintain its overweight in secular growth themes without blowing up overall risk.

On the surface, sector allocations look stable: Technology slipped only from 53.16% to 52.2%, and Consumer Discretionary barely moved. The reality is more nuanced: within tech, Nuveen is migrating from megacap ad and device platforms toward software workflows, data-center networking, and industrial tech.

The new Arista position and higher ServiceNow, Eaton, and Accenture stakes all tilt the tech bucket toward infrastructure and implementation. Alphabet, Meta, Oracle, and the broader platform complex are now modestly smaller funding sources inside that same sector.

Industrials quietly gained ground, rising from 3.78% to 4.26%, driven by big additions to Tesla and Boeing despite notable cuts to Honeywell. That is a clear bet that technologically differentiated industrials with deep order visibility offer better upside than diversified industrial conglomerates.

Health care nudged up from 8.32% to 8.4%, but underneath that, there is a rotation from broad, slower-growth pharma baskets into higher-growth names like Eli Lilly and UnitedHealth. Finance ticked down from 5.29% to 5.12%, as Nuveen trimmed the big banks and insurers to support the build-out in AI adjacency and industrials without increasing overall cyclical beta.

The rest of the book — energy, basic materials, real estate and consumer staples — was managed more tactically, with small trims to Linde and Prologis offset by gentle adds to PepsiCo. The message: keep some diversification, but don’t let it dilute the core AI, infrastructure, and tech-enabled industrial thesis.

Taken together, the quarter’s trades say Nuveen believes the easy money in headline AI and big-tech multiples has been made, but the structural opportunity underneath is still early. They are keeping a large core in Microsoft, Nvidia, Apple and Amazon while rotating incremental dollars into the under-owned parts of the AI stack — networking, workflows, consulting, and industrial applications.

The shift from banks and defensive staples into Arista, ServiceNow, Accenture, Tesla, Boeing, Eli Lilly and UnitedHealth sketches a portfolio built for a world where nominal growth holds up, capex remains elevated, and AI capex spills into broader corporate IT and industrial demand. At the same time, trims in big platforms and legacy pharma show a healthy respect for crowding risk and valuation.

Going forward, expect Nuveen to continue funding high-conviction infrastructure and implementation plays out of mature cash generators. If AI and digitization spread from hyperscalers to the broader economy, this tilt toward the “picks-and-shovels” layer and tech-enabled industrials could drive incremental alpha without materially raising headline sector risk.

If the cycle turns harder than expected, the portfolio may feel some pain in cyclicals like Tesla and Boeing, but the diversified exposure across health care, staples, and real estate suggests they are not all-in on a single macro outcome. The through-line is clear: Nuveen is retooling a tech-heavy book from owning the AI story to owning the AI plumbing.